Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations by Andrew J. Piper-Vallillo, MD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Get full text

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib by Andrew J. Piper-Vallillo, MD, Daniel B. Costa, MD, PhD, MMSc, Marwa A. Sabe, MD, MPH, Aarti Asnani, MD

Get full text

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations by Pedro E.N.S. Vasconcelos, MS, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Get full text

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors by Ikei S. Kobayashi, MD, PhD, William Shaffer, MS, Hollis Viray, MD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Get full text

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene by Zachary R. Schoepflin, MD, Emmeline Academia, PharmD, Soravis A. Osataphan, MD, Deepa Rangachari, MD, Sheida Sharifi, MD, PhD, Paul A. VanderLaan, MD, PhD, Daniel B. Costa, MD, PhD

Get full text

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors by Pedro E.N.S. Vasconcelos, MS, Carol Gergis, MS, Hollis Viray, MD, Andreas Varkaris, MD, PhD, Masanori Fujii, MD, PhD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Get full text